Literature DB >> 22508671

Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs medical treatment.

Frida Leonetti1, Danila Capoccia, Federica Coccia, Giovanni Casella, Giovanni Baglio, Francesca Paradiso, Francesca Abbatini, Angelo Iossa, Emanuele Soricelli, Nicola Basso.   

Abstract

OBJECTIVE: To compare the effect of sleeve gastrectomy vs medical therapy on type 2 diabetes mellitus and other obesity-related comorbidities (obstructive sleep apnea syndrome, hypertension, and dyslipidemia) in prospectively enrolled and matched obese patients with type 2 diabetes.
DESIGN: A prospective cohort study. Morbidly obese patients with type 2 diabetes who either underwent sleeve gastrectomy or conventional therapy were followed up and assessed for their diabetic state and other comorbidities every 3 months for 18 months.
SETTING: Centre for the Surgical-Medical Treatment of Morbid Obesity, Policlinico “Umberto I,” University of Rome “Sapienza,” Italy. PATIENTS: A total of 30 morbidly obese patients with type 2 diabetes who underwent sleeve gastrectomy (group A) and a total of 30 morbidly obese patients with type 2 diabetes who underwent conventional therapy (group B).
RESULTS: In group A, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 41.3 (6.0), 166.6 (68.1) mg/dL, and 7.9% (2.1%), respectively, and, at 18 months, these values were 28.3 (5.4), 96.2 (29.4) mg/dL, and 6.0% (1.5%), respectively. For 80% of patients, diabetes was resolved. With regard to other comorbidities, the prevalence of obstructive sleep apnea syndrome dropped from 50% to 10%, and patients reduced significantly their use of medication for hypertension and dyslipidemia. In group B, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 39.0 (5.5), 183.7 (63.5) mg/dL, and 8.1% (1.7%), respectively, and, at 18 months, these values were 39.8 (5.0), 150 (48) mg/dL, and 7.1% (1.3%), respectively. All patients remained diabetic and continued or increased their level of hypoglycemic therapy. With regard to other comorbidities, we observed an increase in the use of medication for hypertension and dyslipidemia, and the prevalence of obstructive sleep apnea syndrome did not change.
CONCLUSIONS: This study confirms the efficacy of sleeve gastrectomy in the treatment of morbidly obese type 2 diabetic patients when compared with conventional medical treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508671     DOI: 10.1001/archsurg.2012.222

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  30 in total

1.  Sleeve gastrectomy: the ideal option for metabolic surgery?

Authors:  Ricardo Cohen
Journal:  Nat Rev Endocrinol       Date:  2013-08-13       Impact factor: 43.330

Review 2.  The role of bariatric surgery in the treatment of type 2 diabetes: current evidence and clinical guidelines.

Authors:  Michael A Via; Jeffrey I Mechanick
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

3.  A Prospective Randomized Controlled Trial of the Metabolic Effects of Sleeve Gastrectomy with Transit Bipartition.

Authors:  Fernanda R Azevedo; Sergio Santoro; Maria L Correa-Giannella; Marcos T Toyoshima; Daniel Giannella-Neto; Daniela Calderaro; Danielle M Gualandro; Pai C Yu; Bruno Caramelli
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

4.  Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective.

Authors:  Swetha R Palli; John A Rizzo; Natalie Heidrich
Journal:  Obes Surg       Date:  2018-06       Impact factor: 4.129

5.  Long-term Metabolic Effects of Laparoscopic Sleeve Gastrectomy.

Authors:  Danila Capoccia; Federica Coccia; Gloria Guarisco; Moira Testa; Roberta Rendina; Francesca Abbatini; Gianfranco Silecchia; Frida Leonetti
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

6.  Short-Term Assessment of Obstructive Sleep Apnea Syndrome Remission Rate after Sleeve Gastrectomy: a Cohort Study.

Authors:  Marine Timmerman; Damien Basille; Aurélie Basille-Fantinato; Mickaël E Baud; Lionel Rebibo; Claire Andrejak; Vincent Jounieaux; Jean-Daniel Lalau
Journal:  Obes Surg       Date:  2019-11       Impact factor: 4.129

7.  Cardiac remodeling in obese patients after laparoscopic sleeve gastrectomy.

Authors:  Elena Cavarretta; Giovanni Casella; Benedetto Calì; Carmelisa Dammaro; Giuseppe Biondi-Zoccai; Angelo Iossa; Frida Leonetti; Giacomo Frati; Nicola Basso
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

8.  Sera of Obese Type 2 Diabetic Patients Undergoing Metabolic Surgery Instead of Conventional Treatment Exert Beneficial Effects on Beta Cell Survival and Function: Results of a Randomized Clinical Study.

Authors:  Alina Constantin; Mădălina Dumitrescu; Miruna Nemecz; Ariana Picu; Bogdan Smeu; Cristian Guja; Nicoleta Alexandru; Adriana Georgescu; Gabriela Tanko
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

9.  Unmet information and support needs in newly diagnosed thyroid cancer: comparison of adolescents/young adults (AYA) and older patients.

Authors:  Melanie Goldfarb; Jacqueline Casillas
Journal:  J Cancer Surviv       Date:  2014-02-26       Impact factor: 4.442

Review 10.  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.

Authors:  David Bradley; Faidon Magkos; Samuel Klein
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.